Syngene International Ltd. · NSE:SYNGENE
Syngene International — Q1 FY27 Earnings Presentation
12 slides from Syngene International's earnings presentation, Jul 30, 2026
Slide 1: Syngene International Q1 FY27 Earnings Call
Syngene International Q1 FY27 Earnings Call July 30, 2026
Slide 2: Safe Harbor Statement
Safe Harbor Statement Certain statements in this release concerning our future growth prospects are forward-looking statements, which are subject to a number of risks, uncertainties and assumptions that could cause actual results to differ materially from those contemplated in such forward-looking s
Slide 3: Executive Chairperson Remarks - Kiran Mazumdar-Shaw
Executive Chairperson Remarks Kiran Mazumdar-Shaw Executive Chairperson Syngene International Limited Putting Science to Work 3
Slide 4: Executive Chairperson Remarks
Executive Chairperson Remarks FY27 – Transition year: • FY27 is a year of course correction, strategic renewal and disciplined execution under a new leadership team • Focused on restoring sustainable, profitable growth • Building a more diversified and resilient commercial portfolio Strategic Priori
Slide 5: CEO Remarks - Siddharth Mittal
CEO Remarks Siddharth Mittal Managing Director & CEO Syngene International Limited Putting Science to Work 5
Slide 6: MD and CEO Remarks
MD and CEO Remarks The CRDMO industry continues to present significant opportunities for long-term growth, and Syngene's strong scientific foundation, differentiated capabilities and trusted customer relationships position us well to capture them. Immediate focus: Sharpening commercial execution, st
Slide 7: Q1 FY27: Business highlights
Q1 FY27: Business highlights Signed an MoU with the Translational Health Science and Technology Institute, Govt. of India, to support early-phase clinical development, translational research, and First-in-Human (FIH) and Phase I studies. Enhanced Syn.AI with gigascale virtual screening and AI-driven
Slide 8: Q1 FY27: Performance
Q1 FY27: Performance Revenue from Operations Sales Split (Q1 FY27) Rs. 736 Cr ( -16% Y-o-Y) 22% Operating EBITDA & Margin Operating EBITDA Rs. 91 Cr Operating EBITDA Margin 12% PAT 78% Research Services • Before exceptional item: Rs. 1 Cr CDMO business • After exceptional item: Rs. -9 Cr Putting Sci
Slide 9: Capex
Capex Q1 capex of Rs. 70 Cr Net cash balance of Rs.1,541 Cr • Bayview facility in the U.S. Despite the near-term challenges, • Technology platforms and automation our balance sheet remains strong • AI capabilities and strategic priorities We will continue to make investments through the year primari
Slide 10: Closing remarks
Closing remarks • Our priorities are clear • Focus now is executing consistently, enhancing operational performance and delivering better outcomes for our customers Putting Science to Work 10
Slide 11: Q&A
Q&A Putting Science to Work Putting Science to Work
Slide 12: Putting Science to Work
© 2026 Syngene International Limited, Bengaluru, India. All Rights Reserved. Syngene believes the information in this document is accurate as of its publication date; such information is subject to change without notice. Syngene acknowledges the proprietary rights of other companies to the trademark
Syngene International — Q1 FY27 Earnings Presentation on 6ix